Funapide Drug Asset Due Diligence Report 2026

This Funapide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Funapide can convert its Small molecule drug profile and Nav1.7 x Nav1.8 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Funapide (query alias: Funapide)
Modality / target	Small molecule drug; Nav1.7 x Nav1.8; Nav1.7 blockers, Nav1.8 blockers
Highest global status	Phase 2
Originator	Xenon Pharmaceuticals, Inc.
Active developers	Flexion Therapeutics, Inc.

The MCP disease footprint includes Neuralgia, Postherpetic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04826328	Phase 1	Completed	85	Primary endpoint not disclosed in English source
NCT02365636	Phase 2	Completed	300	Primary endpoint not disclosed in English source
NCT02215941	Phase 1	Completed	45	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia.

Phase 2; n=300; evaluation: Not stated in English source. Reported fields: Baseline(Mean) = 5.37 Unit ; Baseline(Mean) = 5.60 Unit

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Primary Osteoarthritis Affecting a Single Knee

Phase 2; n=389; evaluation: Not stated in English source. Reported fields: Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM)(LS Mean) = -20.56 Unit ; Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated Measures (MMRM)(LS Mean) = -23.08 Unit

Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia

Phase 1/2; n=8; evaluation: Not stated in English source. Reported fields: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2(Mean) = 0.24 cooling uses/day (IQR, 0.03 - 0.27); Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2(Mean) = 2.4 cooling uses/day (IQR, NA - NA)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Funapide addresses Neuralgia, Postherpetic. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-09-09	Flexion enters into a global partnership with Xenon to develop and commercialize XEN-402 for post-operative pain.	Phase 2	US$3.0M upfront; US$9.0M milestones; US$12.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Sustained release thermosetting GELS comprising sodium channel blockers and the methods of making the same”. The milestone feed surfaced a patent-application signal described as “Sustained release thermosetting GELS comprising sodium channel blockers and the methods of making the same”. The milestone feed surfaced a patent-application signal described as “Asymmetric synthesis of funapide”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO